Onivyde's mechanism of action involves delivering irinotecan, a topoisomerase I inhibitor, to cancer cells [1]. Irinotecan is a prodrug that is converted in the body to its active form, SN-38 [1]. SN-38 then inhibits topoisomerase I, an enzyme crucial for DNA replication and repair [1]. By blocking this enzyme, SN-38 causes DNA breaks, leading to cell death [1]. Onivyde is a liposomal formulation of irinotecan, meaning the drug is encapsulated within tiny fat-like particles [1]. This liposomal delivery system is designed to alter the drug's pharmacokinetic profile and potentially enhance its delivery to tumor sites while reducing exposure to healthy tissues [2].
What is Onivyde approved to treat?
Onivyde is approved for use in combination with other agents for the treatment of adult patients with metastatic pancreatic adenocarcinoma [2]. Specifically, it is indicated in combination with fluorouracil, leucovorin, and nab-paclitaxel [2].
How does Onivyde's liposomal delivery work?
The liposomal encapsulation of irinotecan in Onivyde aims to prolong the drug's circulation time in the bloodstream [2]. This sustained release can allow for prolonged exposure of cancer cells to the active agent, SN-38 [2]. The liposomes are designed to accumulate preferentially in tumor tissue due to the enhanced permeability and retention (EPR) effect, a phenomenon observed in many tumors where small molecules and nanoparticles can extravasate from blood vessels and accumulate [2].
When does Onivyde's patent protection expire?
Patent expiration dates for Onivyde, like other pharmaceuticals, are complex and can be influenced by various factors including granted patents, exclusivities, and potential patent challenges [3]. Information regarding the specific patent landscape and expiration timelines for Onivyde can be found through specialized databases like DrugPatentWatch.com [3].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment, often in combination regimens, include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [2]. The liposomal formulation may influence the incidence and severity of certain side effects compared to non-liposomal irinotecan [2].
Are there alternatives to Onivyde for pancreatic cancer?
Treatment options for metastatic pancreatic adenocarcinoma are varied and depend on the patient's overall health and disease stage. Chemotherapy regimens often include drugs like gemcitabine, nab-paclitaxel, and fluoropyrimidines. Other targeted therapies and immunotherapies are also areas of research and development for pancreatic cancer.
How does Onivyde compare to other irinotecan formulations?
Onivyde is a liposomal formulation of irinotecan, differentiating it from standard irinotecan hydrochloride injections. The liposomal delivery system is intended to modify the drug's pharmacokinetics, potentially leading to improved efficacy or a different side effect profile [2].
What clinical trials have been conducted for Onivyde?
Clinical trials have evaluated Onivyde in various combinations for metastatic pancreatic cancer, including studies that led to its approval. These trials assess its efficacy and safety compared to or in conjunction with standard chemotherapy agents [2].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [2].
Sources:
[1] https://www.drugbank.ca/drugs/hydrochloride
[2] https://www.onivyde.com/
[3] https://drugpatentwatch.com/